Design Therapeutics, Inc. Common Stock
DSGNDesign Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for serious neurological and rare diseases. They utilize a proprietary genetic medicine platform to create targeted therapies aimed at addressing the underlying causes of these conditions.
Company News
Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider ...
Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy.
